AmerisourceBergen will use a blockchain solution that is expected to streamline and optimize the complex process of pharmaceutical charge-backs while creating greater connectivity for its suppliers and customers.
Ztalmy is the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients aged 2 years old and older, the company said.
The approval means that pharmacists will be allowed to switch out Lantus (insulin glargine) for the Semglee (insulin glargine-yfgn) biosimilar without the required approval from the prescribing physician.
The program can provide access to lifesaving treatments, and allowing pharmacists to prescribe and dispense will make it more effective and accessible for millions of Americans.